Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
21.79
-0.42 (-1.89%)
Mar 6, 2026, 10:08 AM EST - Market open
Arcus Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 247 | 258 | 117 | 112 | 383 | Upgrade
|
| Revenue Growth (YoY) | -4.26% | 120.51% | 4.46% | -70.76% | 391.03% | Upgrade
|
| Cost of Revenue | 523 | 448 | 340 | 288 | 257 | Upgrade
|
| Gross Profit | -276 | -190 | -223 | -176 | 126 | Upgrade
|
| Selling, General & Admin | 110 | 120 | 117 | 104 | 72 | Upgrade
|
| Operating Expenses | 110 | 120 | 117 | 104 | 72 | Upgrade
|
| Operating Income | -386 | -310 | -340 | -280 | 54 | Upgrade
|
| Interest Expense | -8 | -4 | -2 | -2 | - | Upgrade
|
| Interest & Investment Income | 41 | 52 | 41 | 16 | 1 | Upgrade
|
| EBT Excluding Unusual Items | -353 | -262 | -301 | -266 | 55 | Upgrade
|
| Asset Writedown | - | -20 | - | - | - | Upgrade
|
| Pretax Income | -353 | -282 | -301 | -266 | 55 | Upgrade
|
| Income Tax Expense | - | 1 | 6 | 1 | 2 | Upgrade
|
| Net Income | -353 | -283 | -307 | -267 | 53 | Upgrade
|
| Net Income to Common | -353 | -283 | -307 | -267 | 53 | Upgrade
|
| Shares Outstanding (Basic) | 107 | 90 | 74 | 72 | 69 | Upgrade
|
| Shares Outstanding (Diluted) | 107 | 90 | 74 | 72 | 74 | Upgrade
|
| Shares Change (YoY) | 19.20% | 21.76% | 2.78% | -2.70% | 35.04% | Upgrade
|
| EPS (Basic) | -3.29 | -3.14 | -4.15 | -3.71 | 0.76 | Upgrade
|
| EPS (Diluted) | -3.29 | -3.14 | -4.15 | -3.71 | 0.71 | Upgrade
|
| Free Cash Flow | -484 | -176 | -330 | 432 | -282 | Upgrade
|
| Free Cash Flow Per Share | -4.51 | -1.95 | -4.46 | 6.00 | -3.81 | Upgrade
|
| Gross Margin | -111.74% | -73.64% | -190.60% | -157.14% | 32.90% | Upgrade
|
| Operating Margin | -156.28% | -120.15% | -290.60% | -250.00% | 14.10% | Upgrade
|
| Profit Margin | -142.91% | -109.69% | -262.39% | -238.39% | 13.84% | Upgrade
|
| Free Cash Flow Margin | -195.95% | -68.22% | -282.05% | 385.71% | -73.63% | Upgrade
|
| EBITDA | -376 | -300 | -332 | -274 | 58 | Upgrade
|
| EBITDA Margin | -152.23% | -116.28% | -283.76% | -244.64% | 15.14% | Upgrade
|
| D&A For EBITDA | 10 | 10 | 8 | 6 | 4 | Upgrade
|
| EBIT | -386 | -310 | -340 | -280 | 54 | Upgrade
|
| EBIT Margin | -156.28% | -120.15% | -290.60% | -250.00% | 14.10% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 3.64% | Upgrade
|
| Revenue as Reported | 247 | 258 | 117 | 112 | 383 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.